David T W Jones

List of Publications by Year in Descending Order

270 papers	34,967 citations	83 h-index	185 g-index
285 ext. papers	44,438 ext. citations	14.4 avg, IF	6.33 L-index

#	Paper	IF	Citations
270	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival.. *Acta Neuropathologica Communications*, **2022**, 10, 5	7.3	2
269	Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models.. *Cancers*, **2022**, 14,	6.6	3
268	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies.. *Journal of Neuro-Oncology*, **2022**, 157, 37	4.8	
267	Rapid-CNS: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study.. *Acta Neuropathologica*, **2022**, 1	14.3	0
266	The genomic landscape of pediatric renal cell carcinomas.. *IScience*, **2022**, 25, 104167	6.1	0
265	IMMU-04. Transcriptional analysis reveals distinct microenvironmental subgroups across pediatric nervous system tumors. *Neuro-Oncology*, **2022**, 24, i81-i81	1	
264	DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma. *PLoS Computational Biology*, **2021**, 17, e1009562	5	2
263	Genetic and epigenetic characterization of posterior pituitary tumors. *Acta Neuropathologica*, **2021**, 142, 1025-1043	14.3	1
262	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. *Journal of Clinical Oncology*, **2021**, 39, 3839-3852	2.2	8
261	Distinct DNA Methylation Patterns of Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex. *Cellular and Molecular Neurobiology*, **2021**, 1	4.6	
260	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. *Acta Neuropathologica*, **2021**, 141, 281-290	14.3	9
259	The age of adult pilocytic astrocytoma cells. *Oncogene*, **2021**, 40, 2830-2841	9.2	2
258	H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model. *Cancer Cell*, **2021**, 39, 407-422.e13	24.3	13
257	Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. *Acta Neuropathologica*, **2021**, 142, 179-189	14.3	5
256	Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup. *Modern Pathology*, **2021**, 34, 1558-1569	9.8	5
255	Precision medicine in pediatric solid cancers. *Seminars in Cancer Biology*, **2021**,	12.7	4
254	High-Resolution Cartography of the Transcriptome and Methylome Landscapes of Diffuse Gliomas. *Cancers*, **2021**, 13,	6.6	4

253	Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature. *Modern Pathology*, **2021**, 34, 2122-2129	9.8	4
252	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. *Acta Neuropathologica*, **2021**, 141, 85-100	14.3	14
251	Super enhancers define regulatory subtypes and cell identity in neuroblastoma.. *Nature Cancer*, **2021**, 2, 114-128	15.4	15
250	A case series of Diffuse Glioneuronal Tumours with Oligodendroglioma-like features and Nuclear Clusters (DGONC). *Neuropathology and Applied Neurobiology*, **2021**, 47, 464-467	5.2	6
249	Accurate calling of KIAA1549-BRAF fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data. *Neuropathology and Applied Neurobiology*, **2021**, 47, 406-414	5.2	2
248	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. *Neuro-Oncology*, **2021**, 23, 34-43	1	22
247	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. *Acta Neuropathologica*, **2021**, 141, 771-785	14.3	9
246	Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. *Nature Communications*, **2021**, 12, 1269	17.4	12
245	Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation. *Acta Neuropathologica Communications*, **2021**, 9, 20	7.3	2
244	Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator. *Neuro-Oncology*, **2021**, 23, 1576-1585	1	3
243	Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets.. *JCO Precision Oncology*, **2021**, 5, 450-454	3.6	
242	Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). *Acta Neuropathologica*, **2021**, 141, 605-617	14.3	9
241	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. *Journal of Clinical Oncology*, **2021**, 39, 807-821	2.2	7
240	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. *Acta Neuropathologica*, **2021**, 142, 841-857	14.3	7
239	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. *Acta Neuropathologica*, **2021**, 142, 827-839	14.3	5
238	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. *Cancer Discovery*, **2021**, 11, 2764-2779	24.4	22
237	Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. *Cancers*, **2021**, 13,	6.6	1
236	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. *Nature Communications*, **2021**, 12, 5530	17.4	3

235	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. *Acta Neuropathologica*, **2021**, 142, 1065-1069	14.3	1
234	Sarcoma classification by DNA methylation profiling. *Nature Communications*, **2021**, 12, 498	17.4	74
233	Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers. *European Journal of Cancer*, **2020**, 130, 168-181	7.5	4
232	An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data. *Acta Neuropathologica*, **2020**, 140, 237-239	14.3	3
231	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. *BMC Cancer*, **2020**, 20, 523	4.8	11
230	Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation. *Acta Neuropathologica*, **2020**, 139, 1109-1113	14.3	33
229	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. *Nature*, **2020**, 580, 396-401	50.4	47
228	Diffuse leptomeningeal glioneuronal tumor: a double misnomer? A report of two cases. *Acta Neuropathologica Communications*, **2020**, 8, 95	7.3	9
227	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. *Acta Neuropathologica*, **2020**, 140, 409-413	14.3	26
226	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. *Neuro-Oncology*, **2020**, 22, 773-784	1	21
225	Pilocytic astrocytoma demethylation and transcriptional landscapes link bZIP transcription factors to immune response. *Neuro-Oncology*, **2020**, 22, 1327-1338	1	4
224	Genomic footprints of activated telomere maintenance mechanisms in cancer. *Nature Communications*, **2020**, 11, 733	17.4	40
223	Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. *Nature Genetics*, **2020**, 52, 331-341	36.3	168
222	Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation. *Acta Neuropathologica*, **2020**, 139, 403-406	14.3	6
221	Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data. *Nature Protocols*, **2020**, 15, 479-512	18.8	34
220	YAP1-fusions in pediatric NF2-wildtype meningioma. *Acta Neuropathologica*, **2020**, 139, 215-218	14.3	24
219	DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. *The Lancet Child and Adolescent Health*, **2020**, 4, 121-130	14.5	21
218	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. *Acta Neuropathologica*, **2020**, 139, 243-257	14.3	20

217	High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma. *Pathology Research and Practice*, **2020**, 216, 152728	3.4	3
216	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. *Acta Neuropathologica*, **2020**, 139, 583-596	14.3	6
215	Response to trametinib treatment in progressive pediatric low-grade glioma patients. *Journal of Neuro-Oncology*, **2020**, 149, 499-510	4.8	20
214	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. *Cell*, **2020**, 183, 1617-1633.e22	56.2	29
213	Infratentorial IDH-mutant astrocytoma is a distinct subtype. *Acta Neuropathologica*, **2020**, 140, 569-581	14.3	17
212	Drivers underpinning the malignant transformation of giant cell tumour of bone. *Journal of Pathology*, **2020**, 252, 433-440	9.4	5
211	Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns. *Acta Neuropathologica*, **2020**, 140, 765-776	14.3	8
210	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. *Acta Neuropathologica*, **2020**, 139, 193-209	14.3	35
209	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. *Cancer Discovery*, **2020**, 10, 942-963	24.4	65
208	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. *Acta Neuropathologica Communications*, **2019**, 7, 163	7.3	18
207	YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. *Nature Communications*, **2019**, 10, 3914	17.4	39
206	Primary CNS Alveolar Rhabdomyosarcoma: Importance of Epigenetic and Transcriptomic Assays for Accurate Diagnosis. *Journal of Neuropathology and Experimental Neurology*, **2019**, 78, 1073-1075	3.1	4
205	Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. *Acta Neuropathologica*, **2019**, 138, 497-504	14.3	36
204	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. *Lancet Oncology, The*, **2019**, 20, 1011-1022	21.7	182
203	TelomereHunter - in silico estimation of telomere content and composition from cancer genomes. *BMC Bioinformatics*, **2019**, 20, 272	3.6	24
202	Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. *Acta Neuropathologica*, **2019**, 138, 295-308	14.3	27
201	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. *European Journal of Cancer*, **2019**, 114, 27-35	7.5	28
200	Molecular progression of SHH-activated medulloblastomas. *Acta Neuropathologica*, **2019**, 138, 327-330	14.3	2

199	DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma. *Journal of Cancer Research and Clinical Oncology*, **2019**, 145, 1273-1281	4.9	29
198	Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. *Acta Neuropathologica Communications*, **2019**, 7, 24	7.3	49
197	cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF mutation. *Acta Neuropathologica*, **2019**, 137, 683-687	14.3	92
196	DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas. *Neuro-Oncology*, **2019**, 21, 867-877	1	16
195	Challenges to curing primary brain tumours. *Nature Reviews Clinical Oncology*, **2019**, 16, 509-520	19.4	284
194	MYCN amplification drives an aggressive form of spinal ependymoma. *Acta Neuropathologica*, **2019**, 138, 1075-1089	14.3	51
193	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. *Nature Reviews Cancer*, **2019**, 19, 420-438	31.3	52
192	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. *Acta Neuropathologica*, **2019**, 138, 827-835	14.3	24
191	Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles. *Acta Neuropathologica*, **2019**, 137, 1003-1015	14.3	2
190	Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. *Acta Neuropathologica*, **2019**, 137, 837-846	14.3	28
189	The Power of Human Cancer Genetics as Revealed by Low-Grade Gliomas. *Annual Review of Genetics*, **2019**, 53, 483-503	14.5	14
188	The molecular landscape of ETMR at diagnosis and relapse. *Nature*, **2019**, 576, 274-280	50.4	46
187	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. *Cancer Cell*, **2019**, 35, 95-110.e8	24.3	40
186	Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. *Acta Neuropathologica*, **2019**, 137, 521-525	14.3	24
185	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. *Clinical Cancer Research*, **2019**, 25, 1851-1866	12.9	26
184	DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas. *Neuro-Oncology*, **2019**, 21, 214-221	1	13
183	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. *Neuro-Oncology*, **2019**, 21, 95-105	1	55
182	EWSR1-PATZ1 gene fusion may define a new glioneuronal tumor entity. *Brain Pathology*, **2019**, 29, 53-626		29

181	The landscape of genomic alterations across childhood cancers. *Nature*, **2018**, 555, 321-327	50.4	603
180	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. *Acta Neuropathologica*, **2018**, 136, 153-166	14.3	162
179	Unusual paediatric spinal myxopapillary ependymomas: Unique molecular entities or pathological variations on a theme?. *Journal of Clinical Neuroscience*, **2018**, 50, 144-148	2.2	5
178	Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. *Annals of Oncology*, **2018**, 29, 1423-1430	10.3	45
177	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. *Clinical Cancer Research*, **2018**, 24, 1355-1363	12.9	15
176	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study. *Neuro-Oncology*, **2018**, 20, 826-837	1	27
175	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. *Nature*, **2018**, 553, 101-105	50.4	116
174	Systematic identification of suspected anthelmintic benzimidazole metabolites using LC-MS/MS. *Journal of Pharmaceutical and Biomedical Analysis*, **2018**, 151, 151-158	3.5	7
173	DNA methylation-based reclassification of olfactory neuroblastoma. *Acta Neuropathologica*, **2018**, 136, 255-271	14.3	35
172	DNA methylation-based classification of central nervous system tumours. *Nature*, **2018**, 555, 469-474	50.4	992
171	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. *Acta Neuropathologica*, **2018**, 136, 273-291	14.3	99
170	Molecular characterization of medulloblastomas with extensive nodularity (MBEN). *Acta Neuropathologica*, **2018**, 136, 303-313	14.3	9
169	Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. *Modern Pathology*, **2018**, 31, 1246-1256	9.8	58
168	Methylation profiling of paediatric pilocytic astrocytoma reveals variants specifically associated with tumour location and predictive of recurrence. *Molecular Oncology*, **2018**, 12, 1219-1232	7.9	11
167	Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). *Neuro-Oncology*, **2018**, 20, 400-410	1	36
166	Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. *Neuro-Oncology*, **2018**, 20, 848-857	1	111
165	The case for DNA methylation based molecular profiling to improve diagnostic accuracy for central nervous system embryonal tumors (not otherwise specified) in adults. *Journal of Clinical Neuroscience*, **2018**, 47, 163-167	2.2	5
164	Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. *Brain Pathology*, **2018**, 28, 656-662	6	65

163	EGFL7 enhances surface expression of integrin β1 to promote angiogenesis in malignant brain tumors. *EMBO Molecular Medicine*, **2018**, 10,	12	24
162	Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations. *Molecular Cancer Research*, **2018**, 16, 1491-1498	6.6	23
161	Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile. *Acta Neuropathologica*, **2018**, 136, 339-343	14.3	15
160	Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma. *Nature Communications*, **2018**, 9, 2868	17.4	31
159	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. *Lancet Oncology, The*, **2018**, 19, 785-798	21.7	159
158	Methylome analysis and whole-exome sequencing reveal that brain tumors associated with encephalocraniocutaneous lipomatosis are midline pilocytic astrocytomas. *Acta Neuropathologica*, **2018**, 136, 657-660	14.3	12
157	Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma. *Neuro-Oncology*, **2018**, 20, 1517-1524	1	24
156	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. *Acta Neuropathologica*, **2018**, 136, 327-337	14.3	63
155	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. *Acta Neuropathologica*, **2018**, 136, 211-226	14.3	111
154	Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. *Nature Communications*, **2018**, 9, 2378	17.4	50
153	Pediatric low-grade gliomas: next biologically driven steps. *Neuro-Oncology*, **2018**, 20, 160-173	1	76
152	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. *Journal of Clinical Oncology*, **2018**, 36, 1963-1972	2.2	125
151	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. *Journal of Clinical Oncology*, **2018**, JCO2017764720	2.2	34
150	BRAF V600E Status Alone Is Not Sufficient as a Prognostic Biomarker in Pediatric Low-Grade Glioma. *Journal of Clinical Oncology*, **2018**, 36, 96	2.2	13
149	Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors. *Nature Communications*, **2018**, 9, 4760	17.4	37
148	Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location. *Acta Neuropathologica Communications*, **2018**, 6, 117	7.3	48
147	Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERK. *Heliyon*, **2018**, 4, e01065	3.6	0
146	Modern Principles of CNS Tumor Classification **2018**, 117-129		

145	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. *Acta Neuropathologica*, **2018**, 136, 975-978	14.3	5
144	A biobank of patient-derived pediatric brain tumor models. *Nature Medicine*, **2018**, 24, 1752-1761	50.5	71
143	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. *Lancet Oncology, The*, **2018**, 19, 768-784	21.7	95
142	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. *Acta Neuropathologica*, **2018**, 136, 239-253	14.3	73
141	Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. *Cancer Cell*, **2018**, 33, 829-842.e5	24.3	81
140	Duplications of KIAA1549 and BRAF screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for KIAA1549-BRAF fusion detection in pilocytic astrocytomas. *Modern Pathology*, **2018**, 31, 1490-1501	9.8	17
139	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. *Acta Neuropathologica*, **2018**, 136, 293-302	14.3	29
138	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. *Acta Neuropathologica*, **2018**, 136, 181-210	14.3	148
137	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. *Journal of Neuro-Oncology*, **2017**, 132, 255-266	4.8	34
136	Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. *Acta Neuropathologica*, **2017**, 133, 431-444	14.3	78
135	Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. *Leukemia*, **2017**, 31, 2048-2056	10.7	29
134	Spatial heterogeneity in medulloblastoma. *Nature Genetics*, **2017**, 49, 780-788	36.3	80
133	H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. *Acta Neuropathologica*, **2017**, 134, 507-516	14.3	70
132	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. *Acta Neuropathologica*, **2017**, 134, 155-158	14.3	19
131	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. *Lancet Oncology, The*, **2017**, 18, 682-694	21.7	336
130	Chd7 is indispensable for mammalian brain development through activation of a neuronal differentiation programme. *Nature Communications*, **2017**, 8, 14758	17.4	75
129	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. *Acta Neuropathologica*, **2017**, 133, 325-327	14.3	10
128	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. *Cancer Cell*, **2017**, 32, 520-537.e5	24.3	423

127	DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. *Acta Neuropathologica*, **2017**, 134, 965-967	14.3	20
126	Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. *Journal of Clinical Oncology*, **2017**, 35, 2370-2377	2.2	129
125	New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 753-763	7.1	2
124	Pediatric high-grade glioma: biologically and clinically in need of new thinking. *Neuro-Oncology*, **2017**, 19, 153-161	1	125
123	The whole-genome landscape of medulloblastoma subtypes. *Nature*, **2017**, 547, 311-317	50.4	472
122	Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype. *American Journal of Neuroradiology*, **2017**, 38, 1892-1898	4.4	17
121	Molecular Transition of an Adult Low-Grade Brain Tumor to an Atypical Teratoid/Rhabdoid Tumor Over a Time-Course of 14 Years. *Journal of Neuropathology and Experimental Neurology*, **2017**, 76, 655-664	2.1	9
120	Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. *Clinical Sarcoma Research*, **2017**, 7, 9	2.5	30
119	From class waivers to precision medicine in paediatric oncology. *Lancet Oncology, The*, **2017**, 18, e394-e404	24.7	35
118	Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. *Acta Neuropathologica*, **2017**, 133, 417-429	14.3	96
117	Quantification of telomere features in tumor tissue sections by an automated 3D imaging-based workflow. *Methods*, **2017**, 114, 60-73	4.6	10
116	Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. *Brain Pathology*, **2017**, 27, 411-418	6	34
115	confFuse: High-Confidence Fusion Gene Detection across Tumor Entities. *Frontiers in Genetics*, **2017** , 8, 137	4.5	6
114	New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 753-763	7.1	7
113	Droplet digital PCR is a powerful technique to demonstrate frequent FGFR1 duplication in dysembryoplastic neuroepithelial tumors. *Oncotarget*, **2017**, 8, 2104-2113	3.3	25
112	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. *Oncotarget*, **2017**, 8, 11460-11479	3.3	28
111	Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma. *Oncotarget*, **2017**, 8, 104123-104135	3.3	6
110	Pediatric low-grade gliomas: implications of the biologic era. *Neuro-Oncology*, **2017**, 19, 750-761	1	47

109	Gliomatosis cerebri: no evidence for a separate brain tumor entity. *Acta Neuropathologica*, **2016**, 131, 309-319	14.3	59
108	Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. *Acta Neuropathologica*, **2016**, 131, 137-46	14.3	102
107	Evidence of H3 K27M mutations in posterior fossa ependymomas. *Acta Neuropathologica*, **2016**, 132, 635-7	14.3	55
106	Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. *Nature Medicine*, **2016**, 22, 1314-1320	50.5	137
105	Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. *Acta Neuropathologica Communications*, **2016**, 4, 20	7.3	101
104	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. *Journal of Clinical Oncology*, **2016**, 34, 2468-77	2.2	113
103	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. *Nature*, **2016**, 530, 57-62	50.4	234
102	Divergent clonal selection dominates medulloblastoma at recurrence. *Nature*, **2016**, 529, 351-7	50.4	206
101	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. *Acta Neuropathologica*, **2016**, 131, 903-10	14.3	151
100	Methylation-based classification of benign and malignant peripheral nerve sheath tumors. *Acta Neuropathologica*, **2016**, 131, 877-87	14.3	110
99	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. *Neuro-Oncology*, **2016**, 18, 790-6	1	46
98	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. *Cancer Cell*, **2016**, 29, 379-393	24.3	319
97	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. *Cell*, **2016**, 164, 1060-1072	36.2	483
96	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. *Lancet Oncology, The*, **2016**, 17, 484-495	21.7	187
95	TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma. *Oncotarget*, **2016**, 7, 47918-47926	3.3	6
94	Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. *Oncotarget*, **2016**, 7, 61860-61873	3.3	22
93	Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress. *Oncotarget*, **2016**, 7, 28169-82	3.3	44
92	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. *Brain Pathology*, **2016**, 26, 506-16	6	10

91	Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. *Brain Pathology*, **2016**, 26, 199-205	6	25
90	Telomere dysfunction and chromothripsis. *International Journal of Cancer*, **2016**, 138, 2905-14	7.5	34
89	Somatic mutations of DICER1 and KMT2D are frequent in intraocular medulloepitheliomas. *Genes Chromosomes and Cancer*, **2016**, 55, 418-27	5	29
88	FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. *EMBO Journal*, **2016**, 35, 2192-2212	13	44
87	EpCAM (CD326) is differentially expressed in craniopharyngioma subtypes and Rathke's cleft cysts. *Scientific Reports*, **2016**, 6, 29731	4.9	7
86	Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma. *Journal of Neuro-Oncology*, **2016**, 129, 109-21	4.8	22
85	No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients. *Human Genetics*, **2016**, 135, 469-475	6.3	21
84	Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. *Acta Neuropathologica*, **2016**, 132, 149-51	14.3	89
83	Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. *European Journal of Cancer*, **2016**, 65, 91-101	7.5	186
82	Multifocal nerve lesions and LZTR1 germline mutations in segmental schwannomatosis. *Annals of Neurology*, **2016**, 80, 625-8	9.4	16
81	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. *Acta Neuropathologica*, **2015**, 129, 669-78	14.3	220
80	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. *Acta Neuropathologica*, **2015**, 130, 407-17	14.3	194
79	Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. *Nature Communications*, **2015**, 6, 7391	17.4	181
78	Pilocytic astrocytoma: pathology, molecular mechanisms and markers. *Acta Neuropathologica*, **2015**, 129, 775-88	14.3	229
77	Paired box gene 8 (PAX8) expression is associated with sonic hedgehog (SHH)/wingless int (WNT) subtypes, desmoplastic histology and patient survival in human medulloblastomas. *Neuropathology and Applied Neurobiology*, **2015**, 41, 165-79	5.2	2
76	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. *Acta Neuropathologica*, **2015**, 129, 133-46	14.3	313
75	Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. *Neuropathology*, **2015**, 35, 538-44	2	29
74	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. *Cancer Cell*, **2015**, 27, 728-43	24.3	672

73	Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. *Lancet Oncology, The*, **2015**, 16, e293-302	21.7	53
72	A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. *Nature Communications*, **2015**, 6, 10001	17.4	199
71	Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profiles. *Brain Pathology*, **2015**, 25, 202-8	6	54
70	Medulloblastoma and CNS Primitive Neuroectodermal Tumors. *Molecular Pathology Library*, **2015**, 121-142		
69	Mechismo: predicting the mechanistic impact of mutations and modifications on molecular interactions. *Nucleic Acids Research*, **2015**, 43, e10	20.1	57
68	Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age. *Oncotarget*, **2015**, 6, 31844-56	3.3	10
67	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. *Nature*, **2014**, 506, 445-50	50.4	434
66	Connect four with glioblastoma stem cell factors. *Cell*, **2014**, 157, 525-7	56.2	8
65	Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. *Cancer Cell*, **2014**, 25, 393-405	24.3	469
64	Nuclear relocation of STAT6 reliably predicts NAB2-STAT6 fusion for the diagnosis of solitary fibrous tumour. *Histopathology*, **2014**, 65, 613-22	7.3	83
63	Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. *Acta Neuropathologica*, **2014**, 128, 137-49	14.3	93
62	Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. *Nature* , **2014**, 510, 537-41	50.4	296
61	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. *Nature Reviews Cancer*, **2014**, 14, 92-107	31.3	383
60	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. *Acta Neuropathologica*, **2014**, 128, 279-89	14.3	152
59	Cytogenetic prognostication within medulloblastoma subgroups. *Journal of Clinical Oncology*, **2014**, 32, 886-96	2.2	199
58	Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants. *Acta Neuropathologica*, **2014**, 128, 449-52	14.3	28
57	Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. *Neuro-Oncology*, **2014**, 16, 1408-16	1	140
56	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. *Acta Neuropathologica*, **2014**, 128, 561-71	14.3	148

55	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. *Acta Neuropathologica*, **2014**, 128, 551-9	14.3	200
54	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. *Nature*, **2014**, 511, 428-34	50.4	377
53	Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts. *Acta Neuropathologica*, **2014**, 128, 123-36	14.3	46
52	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. *Nature Genetics*, **2014**, 46, 462-6	36.3	296
51	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. *Neuro-Oncology*, **2014**, 16, 1630-8	7	59
50	PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas. *Clinical Cancer Research*, **2014**, 20, 827-36	12.9	22
49	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. *Acta Neuropathologica Communications*, **2014**, 2, 174	7.3	32
48	Arhgap36-dependent activation of Gli transcription factors. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 11061-6	11.5	25
47	Transitioning from genotypes to epigenotypes: why the time has come for medulloblastoma epigenomics. *Neuroscience*, **2014**, 264, 171-85	3.9	36
46	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. *Nature Genetics*, **2013**, 45, 927-32	36.3	550
45	Signatures of mutational processes in human cancer. *Nature*, **2013**, 500, 415-21	50.4	5895
44	Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. *Acta Neuropathologica*, **2013**, 125, 913-6	14.3	194
43	Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. *Acta Neuropathologica*, **2013**, 125, 651-8	14.3	247
42	Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. *Acta Neuropathologica*, **2013**, 125, 351-8	14.3	158
41	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. *Acta Neuropathologica*, **2013**, 125, 373-84	14.3	126
40	Hypermutation of the inactive X chromosome is a frequent event in cancer. *Cell*, **2013**, 155, 567-81	56.2	50
39	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. *Acta Neuropathologica*, **2013**, 126, 907-15	14.3	211
38	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. *Lancet Oncology, The*, **2013**, 14, 1200-7	21.7	226

37	AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. *Acta Neuropathologica*, **2013**, 126, 757-62	14.3	69
36	Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. *Cancer Cell*, **2013**, 24, 660-72	24.3	478
35	The role of chromatin remodeling in medulloblastoma. *Brain Pathology*, **2013**, 23, 193-9	6	31
34	Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. *Lancet Oncology, The*, **2013**, 14, 534-42	21.7	169
33	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. *Acta Neuropathologica*, **2013**, 125, 659-69	14.3	201
32	Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. *Acta Neuropathologica*, **2013**, 126, 291-301	14.3	70
31	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. *Acta Neuropathologica*, **2013**, 126, 917-29	14.3	115
30	Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. *Journal of Clinical Oncology*, **2013**, 31, 2927-35	2.2	290
29	Medulloblastomics: the end of the beginning. *Nature Reviews Cancer*, **2012**, 12, 818-34	31.3	443
28	Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. *Acta Neuropathologica*, **2012**, 124, 615-25	14.3	295
27	LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). *Acta Neuropathologica*, **2012**, 124, 875-81	14.3	87
26	Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. *Cancer Cell*, **2012**, 22, 425-37	24.3	1243
25	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. *Nature*, **2012**, 488, 106-10	50.4	552
24	Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. *Cell*, **2012**, 148, 59-71	56.2	600
23	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature*, **2012**, 482, 226-31	50.4	1655
22	RAF Fusion Genes and MAPK Activation in Pilocytic Astrocytomas **2012**, 99-105		
21	ICGC PedBrain - dissecting the genomic complexity underlying medulloblastoma using whole-genome sequencing. *BMC Proceedings*, **2012**, 6,	2.3	1
20	MAPK pathway activation in pilocytic astrocytoma. *Cellular and Molecular Life Sciences*, **2012**, 69, 1799-811	10.3	152

19	Dissecting the genomic complexity underlying medulloblastoma. *Nature*, **2012**, 488, 100-5	50.4	623
18	MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. *International Journal of Cancer*, **2012**, 131, 1104-13	7.5	55
17	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 515-27	14.3	57
16	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. *Acta Neuropathologica*, **2012**, 123, 473-84	14.3	678
15	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. *Nature*, **2012**, 488, 49-56	50.4	596
14	Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. *Cancer Cell*, **2011**, 20, 143-57	24.3	395
13	Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts. *Acta Neuropathologica*, **2011**, 121, 753-61	14.3	40
12	Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. *Acta Neuropathologica*, **2011**, 121, 763-74	14.3	176
11	Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. *Clinical Cancer Research*, **2011**, 17, 4650-60	12.9	103
10	An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. *Journal of Clinical Investigation*, **2011**, 121, 1344-8	15.9	54
9	IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. *Neuro-Oncology*, **2009**, 11, 341-7	1	435
8	Genome-wide analysis of subependymomas shows underlying chromosomal copy number changes involving chromosomes 6, 7, 8 and 14 in a proportion of cases. *Brain Pathology*, **2008**, 18, 469-73	6	17
7	Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. *Cancer Research*, **2008**, 68, 8673-7	10.1	658
6	Genomic analysis of pilocytic astrocytomas at 0.97 Mb resolution shows an increasing tendency toward chromosomal copy number change with age. *Journal of Neuropathology and Experimental Neurology*, **2006**, 65, 1049-58	3.1	68
5	Drivers underpinning the malignant transformation of giant cell tumour of bone		1
4	TelomereHunter: telomere content estimation and characterization from whole genome sequencing data		11
3	Dissecting telomere maintenance mechanisms in pediatric glioblastoma		4
2	Establishment of a simplified preparation method for single-nucleus RNA-sequencing and its application to long-term frozen tumor tissues		2

List of Publications

1	Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion	2